Obsidian: Fine-tuning therapeutic protein expression with approved drugs
How Obsidian is designing small molecule-controlled proteins for use in cell therapies and beyond
Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with Celgene. Founded by Atlas Venture in 2015, the start-up thinks it can deploy the tech in any modality where proteins can be manufactured.
The centerpieces of Obsidian Therapeutics Inc.’s technology are its drug-responsive domains -- small domains that are fused to a protein of interest. Each domain